Back to Search
Start Over
Clinicians should think twice before prescribing DPP-4 inhibitors for diabetes
- Source :
- Evidence Based Medicine. 21:81-82
- Publication Year :
- 2016
- Publisher :
- BMJ, 2016.
-
Abstract
- While reviewing abstracts in my role as an Evidence Based Medicine editor, I recently encountered a seemingly strange randomised trial of sitagliptin, one of the new dipeptidyl peptidase-4 (DPP-4) inhibitor antidiabetic drugs. Appearing in the New England Journal of Medicine , the trial evaluated the impact of sitagliptin on cardiovascular outcomes in patients with non-ideally controlled type 2 diabetes with established cardiovascular disease, concluding that sitagliptin was both non-inferior and non-superior to placebo in this high-risk group.1 As a primary care physician, my hope for diabetic patients of mine is that a new medication, such as sitagliptin, would be superior to placebo in reducing their high cardiovascular risk. However, in this high-risk population with prevalent cardiovascular disease, sitagliptin seemed to have no impact on cardiovascular outcomes over the median 3-year follow-up of the trial, so the clinical implications of the findings for my patients seemed dubious. I wondered why a trial demonstrating the non-inferiority of sitagliptin to placebo merited appearance in the world's highest impact general medical journal. Of course, a trial such as this—the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)—has a broader audience than front-line physicians. Indeed, on closer inspection, one suspects that …
- Subjects :
- medicine.medical_specialty
education.field_of_study
business.industry
Population
Primary care physician
General Medicine
Evidence-based medicine
Type 2 diabetes
Disease
030204 cardiovascular system & hematology
medicine.disease
Placebo
03 medical and health sciences
0302 clinical medicine
Sitagliptin
Diabetes mellitus
Medicine
030212 general & internal medicine
business
Intensive care medicine
education
medicine.drug
Subjects
Details
- ISSN :
- 14736810 and 13565524
- Volume :
- 21
- Database :
- OpenAIRE
- Journal :
- Evidence Based Medicine
- Accession number :
- edsair.doi...........18efe70d9120c6341a8c8a845e999a17